1,590,000 Shares in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Bought by Boxer Capital Management LLC

Boxer Capital Management LLC bought a new position in shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Free Report) during the 4th quarter, according to its most recent 13F filing with the SEC. The fund bought 1,590,000 shares of the specialty pharmaceutical company's stock, valued at approximately $13,467,000. KalVista Pharmaceuticals comprises 1.1% of Boxer Capital Management LLC's holdings, making the stock its 27th biggest position. Boxer Capital Management LLC owned 3.22% of KalVista Pharmaceuticals as of its most recent filing with the SEC.

Other hedge funds also recently added to or reduced their stakes in the company. SG Americas Securities LLC raised its stake in KalVista Pharmaceuticals by 10.0% in the 4th quarter. SG Americas Securities LLC now owns 14,508 shares of the specialty pharmaceutical company's stock worth $123,000 after acquiring an additional 1,319 shares during the last quarter. Legal & General Group Plc boosted its holdings in KalVista Pharmaceuticals by 22.5% in the fourth quarter. Legal & General Group Plc now owns 8,144 shares of the specialty pharmaceutical company's stock valued at $69,000 after purchasing an additional 1,494 shares during the last quarter. JPMorgan Chase & Co. raised its stake in shares of KalVista Pharmaceuticals by 8.0% during the 3rd quarter. JPMorgan Chase & Co. now owns 22,610 shares of the specialty pharmaceutical company's stock valued at $262,000 after buying an additional 1,670 shares during the last quarter. China Universal Asset Management Co. Ltd. lifted its holdings in shares of KalVista Pharmaceuticals by 24.7% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 10,329 shares of the specialty pharmaceutical company's stock valued at $87,000 after buying an additional 2,043 shares during the period. Finally, AlphaQuest LLC grew its holdings in KalVista Pharmaceuticals by 17.1% during the fourth quarter. AlphaQuest LLC now owns 17,700 shares of the specialty pharmaceutical company's stock worth $150,000 after acquiring an additional 2,588 shares during the period.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on KALV shares. Citizens Jmp raised shares of KalVista Pharmaceuticals to a "strong-buy" rating in a report on Friday, January 31st. JMP Securities assumed coverage on KalVista Pharmaceuticals in a research report on Friday, January 31st. They set an "outperform" rating and a $19.00 target price on the stock. HC Wainwright reaffirmed a "buy" rating and issued a $20.00 price target on shares of KalVista Pharmaceuticals in a report on Friday, March 14th. Jones Trading restated a "buy" rating and issued a $30.00 price objective on shares of KalVista Pharmaceuticals in a research report on Wednesday, March 26th. Finally, Needham & Company LLC reiterated a "buy" rating and set a $28.00 target price on shares of KalVista Pharmaceuticals in a research report on Tuesday, April 8th. Seven equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of "Buy" and a consensus price target of $24.83.

Insider Activity

In other KalVista Pharmaceuticals news, insider Paul K. Audhya sold 3,125 shares of KalVista Pharmaceuticals stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $9.82, for a total value of $30,687.50. Following the completion of the transaction, the insider now directly owns 100,334 shares of the company's stock, valued at $985,279.88. The trade was a 3.02 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, major shareholder Venrock Healthcare Capital Par acquired 4,137 shares of the company's stock in a transaction that occurred on Monday, February 10th. The stock was acquired at an average price of $9.14 per share, with a total value of $37,812.18. Following the acquisition, the insider now directly owns 5,090,582 shares of the company's stock, valued at approximately $46,527,919.48. This represents a 0.08 % increase in their position. The disclosure for this purchase can be found here. In the last 90 days, insiders bought 202,786 shares of company stock valued at $1,880,511 and sold 17,292 shares valued at $184,625. Corporate insiders own 10.50% of the company's stock.

KalVista Pharmaceuticals Price Performance

KalVista Pharmaceuticals stock traded down $0.62 during trading on Tuesday, reaching $12.48. 651,725 shares of the company were exchanged, compared to its average volume of 411,917. The stock's 50 day simple moving average is $11.95 and its two-hundred day simple moving average is $10.41. The company has a market capitalization of $620.65 million, a P/E ratio of -3.43 and a beta of 0.05. KalVista Pharmaceuticals, Inc. has a 52-week low of $7.30 and a 52-week high of $15.50.

KalVista Pharmaceuticals Profile

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).